Latest News
11-08-18 Zogenix Provides Corporate Update and Reports Third Quarter Financial Results 11-07-18 Zogenix to Present at Stifel 2018 Healthcare Conference 11-01-18 Zogenix to Release Third Quarter 2018 Financial Results and Host Conference Call and Webcast on November 8 more »Spotlight on Clinical Studies
The Zogenix study entitled "A Study to Investigate the Efficacy and Safety of ZX008 (Fenfluramine Hydrochloride) as an Adjunctive Therapy in Children and Audlts with Lennox-Gastaut Syndrome" is being conducted for patients with Lennox-Gastaut syndrome who are not adequately controlled on their current seizure medication. For more information, please visit www.clinicaltrials.gov listing (NCT03355209).
more »Scientific Publications
- Effect of ZX008 on Total Seizures in Dravet Syndrome in a Phase 3 Clinical Trial
- ZX008 in Dravet Syndrome: Effect on Convulsive Seizure Frequency in Subjects Who Failed Treatment with Stiripentol Prior to Study 1, Phase 3 Trial
- ZX008 (Fenfluramine HCl Oral Solution) in Dravet Syndrome: Results of a Phase 3, Randomized, Double-Blind, Placebo-Controlled Trial